Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ResMed Inc. filings document operating results, governance actions, capital returns and securities registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and fiscal-year financial results, record board-declared cash dividends and describe the treatment of NYSE common stock and ASX CHESS Depositary Interests in dividend payments.
The company’s regulatory record also covers board composition, director elections, executive officer transitions, compensation arrangements and amendments to the ResMed Inc. 2009 Incentive Award Plan. Proxy materials provide stockholder voting matters, executive compensation disclosure and corporate-governance information for the medical technology company’s public-company structure.
ResMed Inc. Chief Executive Officer Michael J. Farrell exercised options for 8,009 shares of ResMed common stock at $101.64 per share on October 7, 2025, then sold 8,009 shares at a weighted average price of $282.8483 in multiple trades between $280.95 and $283.90 under a Rule 10b5-1 plan adopted October 31, 2024.
After these transactions, he directly held 467,792 ResMed shares, and an additional 2,090 shares were held indirectly through the Lisette and Michael Farrell Family Trust. The options first became exercisable on November 11, 2019 and were scheduled to expire on November 14, 2025, vesting one-third per year.
Form 144 notice for ResMed Inc. (RMD) reports a proposed sale of 8,009 common shares through Fidelity Brokerage Services LLC on 10/07/2025 with an aggregate market value of $2,265,331.98. The filing identifies the securities as acquired under an option granted on 11/14/2018 and lists cash as the payment method.
The notice also discloses three prior sales by the same seller, each of 8,009 shares on 07/07/2025, 08/07/2025, and 09/08/2025 with gross proceeds shown for each transaction. The filer certifies they are not aware of undisclosed material adverse information and includes the standard signature/attestation language.
ResMed Inc. filed a Form 144 disclosing a proposed sale of 4,876 common shares on the NYSE with an aggregate market value of $1,381,956.16, and 146,414,839 shares outstanding listed. The filing shows the securities were acquired on 10/07/2025 under an option granted 11/16/2022, and the proposed sale date is 10/07/2025. The broker named is Fidelity Brokerage Services LLC in Smithfield, RI. The filer certifies there is no undisclosed material adverse information and reports no securities sold in the past 3 months.
ResMed Inc. Chief Financial Officer Brett Sandercock reported insider transactions on 10/01/2025. Under a Rule 10b5-1 plan adopted 2/19/2025, he acquired 2,000 common shares by exercise of options at a strike of $101.64 and sold 3,000 shares at an average price of $274.36, leaving him with 86,745 shares beneficially owned after the transactions. The exercised options were originally exercisable beginning 11/11/2019 and expire 11/14/2025; the options vest 1/3 per year. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
ResMed insider Michael J. Rider, who serves as Global General Counsel and Secretary, reported a sale of 100 shares of ResMed common stock at a price of $274.36 per share on 10/01/2025. The sale was executed under a Rule 10b5-1 plan adopted on 02/28/2025. Following the reported transaction, Mr. Rider beneficially owns 11,327 shares, held directly. The Form 4 is signed and dated 10/02/2025.
ResMed reports continued product and digital expansion in fiscal 2025 while navigating operational headwinds. The company launched new patient interfaces (AirTouch N30i, AirFit F40), expanded its AirSense 11 and AirCurve 11 platforms globally, and introduced Dawn, a generative-AI powered sleep-health assistant. Over the last 12 months ResMed increased cloud-connectable devices from 26 million to over 30 million, added 5 million patients to AirView 33 million), grew myAir users from 8.3 million to >10.3 million, and added ~15 million residential-care patient accounts 165 million).
Management reports double-digit revenue and EPS growth with expanding margins, disciplined capital deployment including share buybacks and dividend growth, and continued R&D investment (6–7% of revenue). Governance changes include board refreshment with new directors from BD and AbbVie, the planned retirement of Richard Sulpizio, an enhanced Compliance, Privacy and Quality committee, and a strengthened clawback policy. The company discloses a CEO-to-median-employee pay ratio of about 187:1.
ResMed (RMD) filed a Form 144 proposing the sale of 100 shares of common stock through Fidelity Brokerage Services with an approximate market value of $27,436, scheduled for 10/01/2025. The shares were acquired by restricted stock vesting on 11/11/2023 and were granted as compensation. The filer previously sold 66 shares on 07/01/2025 for $16,961.34 and 50 shares on 08/01/2025 for $14,095.00. The filing includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.
Form 144 notice for ResMed Inc. (RMD) shows proposed sales of common stock by an individual affiliated with the issuer. The filing lists a broker (Fidelity Brokerage Services) and an intended sale of 3,000 shares with an aggregate market value of $823,080 to be sold on 10/01/2025 on the NYSE. The filer acquired 1,000 shares on 11/11/2022 by restricted stock vesting (compensation) and 2,000 shares on 10/01/2025 via option exercise (options granted 11/14/2018) with cash payment. The form also discloses sales by the same person totaling 9,883 shares in the prior three months with gross proceeds reported for each sale.
Michael J. Farrell, Chief Executive Officer of ResMed Inc. (RMD), reported transactions on Form 4 relating to common stock and stock options. On 09/08/2025 he acquired 8,009 shares at $101.64 per share under a Rule 10b5-1 plan adopted October 31, 2024, and sold 8,009 shares in multiple trades at a weighted-average price of $278.1359 (trade prices ranged $275.27–$279.57). Following the reported transactions his direct beneficial ownership is reported as 475,801 shares after the purchase and 467,792 shares after the sale, with an additional 2,090 shares held indirectly via the Lisette and Michael Farrell Family Trust. He also reports holding 16,020 options exercisable through 11/14/2025; options vest one-third per year.
ResMed Inc. (RMD) Form 144 reports a proposed sale of 8,009 common shares through Fidelity Brokerage Services with an aggregate market value of $2,227,590.84. The filing lists approximately 146,414,839 shares outstanding and an intended sale date of 09/08/2025 on the NYSE.
The shares were acquired under an option granted on 11/14/2018 and shown as acquired on 09/08/2025, with payment in cash. The filer previously sold 8,009 shares on 06/09/2025, 07/07/2025 and 08/07/2025 with gross proceeds of $2,011,909.65, $2,056,076.09 and $2,238,378.55, respectively.